Imaging Brain Tumors With FACBC and Methionine

• Register: ClinicalTrials.gov
• Last refreshed on: 5 November 2012
• Main ID: NCT00597246
• Date of registration: 09/01/2008
• Primary sponsor: Memorial Sloan-Kettering Cancer Center
• Public title: Imaging Brain Tumors With FACBC and Methionine
• Scientific title: Imaging Brain Tumors With FACBC and Methionine
• Date of first enrolment: May 2003
• Target sample size: 30
• Recruitment status: Active, not recruiting
• URL: http://clinicaltrials.gov/show/NCT00597246
• Study type: Interventional
• Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Countries of recruitment

United States

Contacts

• Name: Ronald blasberg, MD
• Affiliation: Memorial Sloan-Kettering Cancer Center

Key inclusion & exclusion criteria

Inclusion Criteria:

- Registered patient at MSKCC.

- Child-bearing age females must be non-pregnant, non-lactating, and must be using
adequate contraception or surgically sterile.

- Karnofsky score of 60 or greater.

- Children that can sit still for 60-90 minutes, without sedation, will be included in
this protocol.

Exclusion Criteria:

- Patient cannot tolerate lying still for 90 minute sessions in the PET tomograph.



Age minimum: N/A
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Brain Cancer

CNS Cancer

Intervention(s)

Drug: FACBC, Methionine

Other: PET Scan

Primary Outcome(s)

Demonstrate [18F]-FACBC has equal or better brain tumor imaging characteristics compared to [11C]-methionine. Det biodistribution & clearance of 3-[18F]-FACBC in diff tissues/organs of body. [Time Frame: 6 years]

Secondary Outcome(s)

Look for potential correlations bet subsequent MR & PET results obtained from patients enrolled and patients' subsequent medical treatment, progression of tumor & survival. [Time Frame: 6 years]

Secondary ID(s)

03-028

Source(s) of Monetary Support

Please refer to primary and secondary sponsors